Jaya Aysola’s Remarks from UN Panel on Health Care for the Disabled
LDI Senior Fellow Calls for a Major Upgrade in Best Practices
In Their Own Words
Will TrumpRx Lower Prescription Drug Prices?
LDI Fellow Argues the Plan Misses Key Drivers of High Costs and Points Instead to Public-Sector Solutions
Print:
This Commentary originally appeared in U.S. News & World Report on March 26, 2026.
Millions of people across the U.S. ration and skip medicines because of an unaffordable system shaped by powerful corporate actors. To tackle this problem, President Donald Trump heralded TrumpRx, a government-branded drug discount website launched a month ago, as “one of the most transformative health care initiatives of all time.”
But the early returns tell a different story: Only 54 drugs are listed on the platform. As Stat News reported earlier this month, web traffic has plummeted from its launch-day peak.
Indeed, patients and policymakers should not confuse a glossy website with real reform. Our work researching drug pricing and healthcare affordability points in a different direction: public-sector innovations already being developed and tested across the country.
The limits of TrumpRx are significant. While the administration pitches the initiative as a transparent marketplace where patients can shop for the best price, it requires out-of-pocket purchasing, which benefits those who can afford to pay. For many drugs on the platform, monthly costs remain substantial. Consider GLP-1 medications for diabetes and weight loss: They still cost $200-$300 per month on TrumpRx, a price point that remains unaffordable for most Americans. And at least half of the drugs already have more affordable generic options available elsewhere.
Read the full Commentary here.
Authors
Victor Roy, MD, PhD
Assistant Professor, Department of Family Medicine and Community Health, Perelman School of Medicine
Mara Heneghan, MA
Associate Director, Health and Political Economy Project, Institute on Race, Power and Political Economy, The New School
More from LDI
States Weigh in on Trump Administration’s Medicaid Fraud Push
LDI/Tradeoffs Virtual Seminar Explores the New Federal Actions and Why Fraud is Hard to Measure
Pregnancy Can Turn Deadly Before Prenatal Care Begins
LDI Fellow and OB-GYN Calls for Faster Testing and Better Early-Pregnancy Care
From Secret Health Care Prices to Too Much Information
Why a 2020 Federal Price Transparency Initiative has yet to Produce a Consumer Shopping Revolution
Lung Cancer Screening Isn’t Enough. Pay People to Quit Smoking.
Cash Incentives Doubled Quit Rates Among High-Risk Patients, Penn LDI Study Finds
Securing Abandoned Houses May Prevent Fatal Opioid Overdoses
Penn Study Finds Fewer Fatal Overdoses on Blocks Where Vacant Buildings were Sealed